President Trump's plans to impose higher tariffs on pharmaceuticals may disrupt decades of tariff-free trade, affecting drug affordability and availability. This could impact EU pharmaceutical exports, including vital medications such as cancer treatments and flu vaccines. With the high profit margins in the U.S. market, European pharmaceutical companies may respond by increasing production domestically. Concerns emerge over the potential implications for public health as critical medications could be affected by trade tensions and tariffs.
"Putting them in the middle of a trade war is highly concerning," said Lea Auffret, who heads international affairs for BEUC, the European Consumer Organization.
European companies could react to Mr. Trump's tariffs in a range of ways. Some pharmaceutical companies trying to dodge the tariffs have already announced plans to increase production in the United States.
Collection
[
|
...
]